Vascular calcification in chronic kidney disease: A clinical review

Journal of Renal Care

Volumn 35, Issue SUPPL. 1, 2009, Pages 45-50

  Eddington, Helen ^a   Sinha, Smeeta ^a   Kalra, Philip A ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bone disease; Cardiovascular; Chronic kidney disease; Haemodialysis

Indexed keywords

CALCINOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EVIDENCE BASED PRACTICE; HOSPITALIZATION; HUMAN; NEPHROLOGY; PREVALENCE; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; VASCULAR DISEASE;

CALCINOSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; EVIDENCE-BASED PRACTICE; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PREVALENCE; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 61649101251     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2009.00059.x     Document Type: Review

References (36)

1. Adragao T., Pires A., Lucas C. et al. (2004). A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrology Dialysis Transplantation 19, 1480-1488.
2. Blacher J., Guerin A.P., Pannier B. et al. (1999). Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99, 2434-2439.
3. Block G.A., Klassen P.S., Lazarus J.M. et al. (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology 15, 2208-2218.
4. Block G.A., RaggiP., Bellasi A. et al. (2007). Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International 71, 438-441.
5. Block G.A., Spiegel D.M., Ehrlich J. et al. (2005). Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International 68, 1815-1824.
6. Block G.A., Zeig S., Sugihara J. et al. (2008). Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrology Dialysis Transplantation 23, 2311-1318.
7. Braun J., Oldendorf M., Moshage W. et al. (1996). Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. American Journal of Kidney Diseases 27, 394-401.
8. Brown A.J., Finch J. & Slatopolsky E. (2002). Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. Journal of Laboratory and Clinical Medicine 139, 279-284.
9. Chertow G.M., Burke S.K. & Raggi P. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International 62, 245-252.
10. Covic A., Gusbeth-Tatomir P. & Goldsmith D.J. (2005). Arterial stiffness in renal patients: an update. American Journal of Kidney Diseases 45, 965-977.
11. Coyne D.W., Grieff M., Ahya S.N. et al. (2002). Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. American Journal of Kidney Diseases 40, 1283-1288.
12. Eknoyan G., Levin A. & Levin N.W. (2003). National Kidney Foundation: K/DOQI clinical practice guidelines: Bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases 42, S1-S201.
13. Foley R.N., Parfrey P.S. & Sarnak M.J. (1998). Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 32, S112-S119.
14. Goodman W.G., Goldin J., Kuizon B.D. et al. (2000). Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New England Journal of Medicine 342, 1478-1483.
15. Hak A.E., Pols H.A., van Hemert A.M. et al. (2000). Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arteriosclerosis Thrombosis and Vascular Biology 20, 1926-1931.
16. Hujairi N.M., Afzali B. & Goldsmith D.J. (2004). Cardiac calcification in renal patients: what we do and don't know. American Journal of Kidney Diseases 43, 234-243.
17. Jean G., Chazot, C. & Charra B. (2007). 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroigism: effect on bone markers. Clinical Nephrology 68, 63-64.
18. Kauppila L.I., Polak J.F., Cupples L.A. et al. (1997). New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132, 245-250.
19. Kiel D.P., Kauppila L.I., Cupples L.A. et al. (2001). Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcified Tissue International 68, 271-276.
20. Lien Y.H., Silva A.L. & Whittman D. (2005). Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation 20, 1232-1237.
21. London G.M., Guerin A.P., Marchais S.J. et al. (2003). Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 18, 1731-1740.
22. London G.M., Marchais S.J. & Guerin A.P. (2004a). Arterial stiffness and function in end-stage renal disease. Advances in Chronic Kidney Disease 11, 202-209.
23. London G.M., Marty C., Marchais S.J. et al. (2004b). Arterial calcifications and bone histomorphometry in end-stage renal disease. Journal of the American Society of Nephrology 15, 1943-1951.
24. Lopez I., Guilera-Tejero E., Mendoza F.J. et al. (2006). Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. Journal of the American Society of Nephrology 17, 795-804.
25. Marcovitz P.A., Tran H.H., Franklin B.A. et al. (2005). Usefulness of bone mineral density to predict significant coronary artery disease. American Journal of Cardiology 96, 1059-1063.
26. Moe S., Drüeke T, Cunningham J. et al. (2006). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 69, 1945-1953.
27. Moe S.M., O'neill K.D., Fineberg N. et al. (2003). Assessment of vascular calcification in ESRD patients using spiral CT. Nephrology Dialysis Transplantation 18, 1152-1158.
28. Querfeld U. (2002). Is atherosclerosis accelerated in young patients with end-stage renal disease? The contribution of paediatric nephrology. Nephrology Dialysis Transplantation 17, 719-722.
29. Qunibi W, Moustafa M., Muenz L.R. et al. (2008). A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. American Journal of Kidney Diseases 51, 952-965.
30. Ross E.A., Tian J., Abboud H. et al. (2008). Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. American Journal of Nephrology 28, 97-106.
31. Samelson E.J., Kiel D.P., Broe K.E. et al. (2004). Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. American Journal of Epidemiology 159, 589-595.
32. Schulz E., Arfai K., Liu X. et al. (2004). Aortic calcification and the risk of osteoporosis and fractures. Journal of Clinical Endocrinology and Metabolism 89, 4246-4253.
33. Schwarz U., Buzello M., Ritz E. et al. (2000). Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrology Dialysis Transplantation 15, 218-223.
34. Suki W.N., Zabaneh R., Cangiano J.L. et al. (2007). Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International 72, 1130-1137.
35. Teng M., Wolf M., Lowrie E. et al. (2003). Survival of patients undergoing haemodialysis with paracalcitol or calcitriol therapy. New England Journal of Medicine 349, 446-456.
36. Wanner C., Krane V., Marz W. et al. (2005). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine 353, 238-248.